Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase
暂无分享,去创建一个
[1] T. Weikl,et al. Selected‐fit versus induced‐fit protein binding: Kinetic differences and mutational analysis , 2008, Proteins.
[2] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[3] D. Graham,et al. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. , 2009, Journal of molecular biology.
[4] Meitian Wang,et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. , 2006, Journal of molecular biology.
[5] R. Nussinov,et al. The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.
[6] Meitian Wang,et al. Crystal Structures of the RNA-dependent RNA Polymerase Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-nucleoside Inhibitors* , 2005, Journal of Biological Chemistry.
[7] Ioan Andricioaei,et al. On the calculation of entropy from covariance matrices of the atomic fluctuations , 2001 .
[8] J. Duan,et al. N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. , 2010, Bioorganic & medicinal chemistry letters.
[9] S. Harper,et al. Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase , 2003, Journal of Virology.
[10] J. Lescar,et al. RNA-dependent RNA polymerases from flaviviruses and Picornaviridae. , 2009, Current opinion in structural biology.
[11] R. Bartenschlager,et al. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. , 2006, Journal of hepatology.
[12] Oliver F. Lange,et al. Can principal components yield a dimension reduced description of protein dynamics on long time scales? , 2006, The journal of physical chemistry. B.
[13] J. Jiricny,et al. RNA-dependent RNA polymerase of hepatitis C virus. , 1996, Methods in enzymology.
[14] Satoru Ikeda,et al. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. , 2006, Journal of medicinal chemistry.
[15] Hui Li,et al. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[16] S. Vasavanonda,et al. Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. , 2006, Biochemistry.
[17] Gordana Ivosev,et al. Dimensionality reduction and visualization in principal component analysis. , 2008, Analytical chemistry.
[18] P. Simister,et al. A Comprehensive Structure-Function Comparison of Hepatitis C Virus Strain JFH1 and J6 Polymerases Reveals a Key Residue Stimulating Replication in Cell Culture across Genotypes , 2011, Journal of Virology.
[19] Shichen Wang,et al. Molecular Dynamics Analysis Reveals Structural Insights into Mechanism of Nicotine N-Demethylation Catalyzed by Tobacco Cytochrome P450 Mono-Oxygenase , 2011, PloS one.
[20] K. Buck. Comparison of The Replication of Positive-Stranded Rna Viruses of Plants and Animals , 1996, Advances in Virus Research.
[21] N. Habuka,et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. , 1999, Structure.
[22] Coray M. Colina,et al. Molecular Dynamics Simulations of Viral RNA Polymerases Link Conserved and Correlated Motions of Functional Elements to Fidelity , 2011, Journal of Molecular Biology.
[23] J. E. Robinson,et al. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[24] A. Ramanathan,et al. Computational identification of slow conformational fluctuations in proteins. , 2009, The journal of physical chemistry. B.
[25] M. Komatsu,et al. The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. , 2002, Biochimica et biophysica acta.
[26] Kyoung Tai No,et al. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. , 2009, Bioorganic & medicinal chemistry.
[27] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[28] Matthias Rarey,et al. Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations , 2007, J. Chem. Inf. Model..
[29] David L. Beveridge,et al. Dynamical allosterism in the mechanism of action of DNA mismatch repair protein MutS. , 2011, Biophysical journal.
[30] Robert A. Love,et al. Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme , 2003, Journal of Virology.
[31] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[32] Isabelle Bougie,et al. Characterization of the Metal Ion Binding Properties of the Hepatitis C Virus RNA Polymerase* , 2003, The Journal of Biological Chemistry.
[33] P. Simister,et al. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. , 2011, Journal of molecular biology.
[34] D. Lamarre,et al. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. , 2004, Nucleic acids research.
[35] Hui Li,et al. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. , 2009, Journal of medicinal chemistry.
[36] Alexander D. MacKerell,et al. Atomistic Models and Force Fields , 2001 .
[37] P. Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection , 2009, Expert opinion on therapeutic patents.
[38] Francisco Parra,et al. Structure and function of RNA replication. , 2006, Annual review of microbiology.
[39] S. LaPlante,et al. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. , 2004, Angewandte Chemie.
[40] N. Walker,et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. , 2006, Journal of molecular biology.
[41] Ching-Hsing Yu,et al. Systematic study of anharmonic features in a principal component analysis of gramicidin A. , 2010, Biophysical journal.
[42] Z. A. Wood,et al. Role of packing defects in the evolution of allostery and induced fit in human UDP-glucose dehydrogenase. , 2011, Biochemistry.
[43] Vladimir D. Axelrod,et al. Modulation of Hepatitis C Virus RNA-dependent RNA Polymerase Activity by Structure-based Site-directed Mutagenesis* , 2002, Journal of Biological Chemistry.
[44] Interdomain communication in HCV polymerase abolished by small-molecule inhibitors , 2005 .
[45] Meitian Wang,et al. Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.
[46] Isabelle Bougie,et al. Effect of Metal Ion Binding on the Structural Stability of the Hepatitis C Virus RNA Polymerase* , 2004, Journal of Biological Chemistry.
[47] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[48] R. Chopra,et al. Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 , 2008, Antimicrobial Agents and Chemotherapy.
[49] J. E. Robinson,et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. , 2009, Bioorganic & medicinal chemistry letters.
[50] M. Cummings,et al. 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus , 2010, Journal of Virology.
[51] Charles M. Rice,et al. Unravelling hepatitis C virus replication from genome to function , 2005, Nature.
[52] E. H. Rydberg,et al. Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. , 2009, Journal of medicinal chemistry.
[53] R. Francesco,et al. Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. , 1996, The EMBO journal.
[54] Nuria Verdaguer,et al. A comparison of viral RNA-dependent RNA polymerases. , 2006, Current opinion in structural biology.
[55] Youhoon Chong,et al. Identification of Novel HCV RNA‐dependent RNA polymerase Inhibitors Using Pharmacophore‐Guided Virtual Screening , 2008, Chemical biology & drug design.
[56] Isabelle Bougie,et al. Metal ion-binding studies highlight important differences between flaviviral RNA polymerases. , 2009, Biochimica et biophysica acta.
[57] M. Cummings,et al. 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.
[58] Dusanka Janezic,et al. Harmonic analysis of large systems. I. Methodology , 1995, J. Comput. Chem..
[59] Jeffrey A Pfefferkorn,et al. Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.
[60] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[61] Dashyant Dhanak,et al. Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. , 2009, Bioorganic & medicinal chemistry letters.
[62] Haralambos Sarimveis,et al. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. , 2007, Bioorganic & medicinal chemistry.
[63] A S Perelson,et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.
[64] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[65] R. Nussinov,et al. Allostery and population shift in drug discovery. , 2010, Current opinion in pharmacology.
[66] C. Kao,et al. Conformations of the monomeric hepatitis C virus RNA-dependent RNA polymerase , 2010 .